Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to $27.7 million.

  • Oncology Institute's Cash & Current Investments fell 4165.23% to $27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year decrease of 4165.23%. This contributed to the annual value of $49.7 million for FY2024, which is 4005.31% down from last year.
  • Per Oncology Institute's latest filing, its Cash & Current Investments stood at $27.7 million for Q3 2025, which was down 4165.23% from $30.3 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Cash & Current Investments ranged from a high of $115.2 million in Q4 2021 and a low of $11.5 million during Q3 2021
  • Its 5-year average for Cash & Current Investments is $56.1 million, with a median of $49.7 million in 2024.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 182020.67% in 2021, then tumbled by 4577.17% in 2024.
  • Over the past 5 years, Oncology Institute's Cash & Current Investments (Quarter) stood at $115.2 million in 2021, then plummeted by 35.92% to $73.8 million in 2022, then grew by 12.26% to $82.9 million in 2023, then plummeted by 40.05% to $49.7 million in 2024, then plummeted by 44.32% to $27.7 million in 2025.
  • Its Cash & Current Investments stands at $27.7 million for Q3 2025, versus $30.3 million for Q2 2025 and $39.7 million for Q1 2025.